Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)

被引：0
|
作者：
Liao, M. [1 ]
Yang, Y. [2 ,5 ]
Jiang, H. [3 ]
Huang, J. [1 ]
Liu, C. [4 ]
Yang, Y. [2 ,5 ]
Xie, K. [6 ]
Luo, X. [7 ]
Zhou, J. [1 ]
Wang, X. [8 ]
Wu, H.
Zeng, Y. [9 ]
Li, Q. [5 ]
机构：
[1] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Liver Transplant Ctr, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China
[8] Sichuan Univ, West China Hosp, Div Abdominal Tumor Multimodal Treatment, Dept Radiat Oncol, Chengdu, Peoples R China
[9] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
中国博士后科学基金;
关键词：
D O I：
10.1016/j.annonc.2024.08.1026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
966P
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348)
    Lim, Ho Yeong
    Heo, Jeong
    Kim, Tae-You
    Tai, Wai Meng David
    Kang, Yoon-Koo
    Lau, George
    Kudo, Masatoshi
    Tak, Won Young
    Watras, Magdalena
    Ali, Sajid K.
    Negro, Alejandra
    Abou-Alfa, Ghassan K.
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] Short-term preoperative treatment with sorafenib for patients with resectable hepatocellular carcinoma (HCC): results of the BIOSHARE neoadjuvant phase II study from GERCOR IRC
    Bouattour, Mohamed
    Fartoux, Laetitia
    Rosmorduc, Olivier
    Vibert, Eric
    Costentin, Charlotte E.
    Soubrane, Olivier
    Scatton, Olivier
    Ronot, Maxime
    Castera, Laurent
    Garnier, Muriel
    De Gramont, Armand
    Belghiti, Jacques
    Paradis, Valerie
    Tijeras-Raballand, Annemila
    Hadengue, Alexandra
    Brusquant, David
    Chibaudel, Benoist
    Raymond, Eric
    Faivre, Sandrine
    HEPATOLOGY, 2015, 62 : 420A - 420A
  • [43] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.
    Zhang, Nan
    Li, Jiongyuan
    Piao, Mingjian
    Li, Chengjie
    Xun, Ziyu
    Zhang, Longhao
    Wang, Yanyu
    Liu, Kai
    Wang, Shanshan
    Wang, Hanping
    Zhao, Hai-Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
    Vogel, A.
    Saborowski, A.
    Siegler, G. M.
    Siebler, J.
    Lindig, U.
    Schultheiss, M.
    Mueller, T.
    Simon, H.
    Joeckel, C.
    Muller, D. W.
    Al-Batran, S-E.
    De Toni, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S598 - S598
  • [46] Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.
    Jiao Shun Chang
    Bai Li
    Dong Jiahong
    Bai Chunmei
    Hu Chunhong
    Shen Liangfang
    Qin Qun
    Bai Yuxian
    Fan Jia
    Zang Aimin
    Zhu Yanyun
    Han Chun
    Li Juan
    Zhang Pengfei
    Ye Sisi
    Kang Xindan
    Qiao Qian
    Wang, Zhongmin Maxwell
    Li Baiyong
    Xia Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [47] Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
    Finn, R. S.
    Kudo, M.
    Merle, P.
    Meyer, T.
    Qin, S.
    Ikeda, M.
    Xu, R.
    Edeline, J.
    Ryoo, B-Y.
    Ren, Z.
    Cheng, A-L.
    Galle, P. R.
    Kaneko, S.
    Kumada, H.
    Wang, A.
    Mody, K.
    Dubrovsky, L.
    Siegel, A. B.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1401
  • [48] Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
    Peng, Linhui
    Chen, Tao
    Chen, Yajin
    Xu, Yunxiuxiu
    Wang, Jie
    Chen, Jie
    Li, Yong
    Huang, Pinbo
    Hu, Xiao
    Zhong, Guoping
    Chen, Xi
    Ye, Congting
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study
    Yu, Nuo
    Chen, Xiankai
    Li, Jiao
    Kang, Xiaozheng
    Wang, Zhen
    Zhang, Ruixiang
    Qin, Jianjun
    Li, Yong
    Zheng, Qingfeng
    Feng, Guojie
    Deng, Lei
    Zhang, Tao
    Wang, Wenqing
    Liu, Wenyang
    Wang, Jianyang
    Feng, Qinfu
    Lv, Jima
    Zhou, Zongmei
    Xiao, Zefen
    Bi, Nan
    Li, Yin
    Wang, Xin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (12) : 1038 - 1046
  • [50] Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study
    Chon, H.
    Heo, J.
    Evans, T. R. J.
    Kim, D. Y.
    Lim, H. Y.
    Macarulla Mercade, T.
    Gomez Martin, C.
    Moreno Garcia, V.
    Ryu, M. H.
    Baumann, P.
    Bhoi, S.
    Jensen, M.
    Tunblad, K.
    Wallberg, H.
    Oberg, F. G.
    Reig Monzon, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S672 - S673
12345